Meditrina hospital, Kollam, Kerala, India.
Meditrina hospital, Kollam, Kerala, India.
Indian Heart J. 2021 Jul-Aug;73(4):434-439. doi: 10.1016/j.ihj.2021.06.006. Epub 2021 Jul 1.
To analyse the feasibility, safety and procedural outcomes of percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) through retrograde approach using single catheter.
Our study was a retrospective observational study that enrolled patients who underwent retrograde CTO PCI using a single catheter between June 2016 and February 2020. Clinical success was defined as successful completion of CTO PCI without associated in-hospital major clinical complications like death, myocardial infarction, stroke or urgent revascularisation. Technical success was defined as successful completion of CTO PCI using single catheter and minimum diameter stenosis of <30% with thrombolysis in myocardial infarction (TIMI) flow grade 3, without significant side branch occlusion, flow-limiting dissection, distal embolization, or angiographic thrombus.
Totally 102 patients underwent retrograde CTO PCI during the study period. Out of which, 15 cases were attempted using single catheter. Mean age of the population was 59.1 ± 8.9 years (males: 86.7%) and the left ventricular ejection fraction (LVEF) was (61% ± 9.1%). Mean number of diseased arteries was 2.1 ± 0.7, length of the CTO was 25.5 ± 7.4 mm and J-CTO score was 2.3 ± 0.7. We achieved a technical success rate of 73.3% using single catheter, and the overall clinical success (Including single catheter and ping pong) was obtained in 86.7% cases. One patient (6.7%) developed cardiac tamponade and none of study population required dialysis for contrast induced acute kidney injury (CI-AKI) CONCLUSIONS: Retrograde CTO PCI using single catheter is a technically challenging procedure when compared with other CTO PCI. Our study demonstrated acceptable outcomes which is comparable to other antegrade and retrograde CTO PCI registries.
分析经逆行途径使用单导管进行慢性完全闭塞(CTO)经皮冠状动脉介入治疗(PCI)的可行性、安全性和程序结果。
我们的研究是一项回顾性观察性研究,纳入了 2016 年 6 月至 2020 年 2 月期间使用单导管进行逆行 CTO PCI 的患者。临床成功定义为 CTO PCI 成功完成,无院内重大临床并发症,如死亡、心肌梗死、卒中和紧急血运重建。技术成功定义为使用单导管成功完成 CTO PCI,最小直径狭窄<30%,心肌梗死溶栓治疗(TIMI)血流分级 3,无明显侧支闭塞、限制血流夹层、远端栓塞或血管造影血栓。
研究期间共有 102 例患者接受逆行 CTO PCI,其中 15 例尝试使用单导管。人群的平均年龄为 59.1±8.9 岁(男性:86.7%),左心室射血分数(LVEF)为(61%±9.1%)。病变血管数平均为 2.1±0.7 条,CTO 长度为 25.5±7.4mm,J-CTO 评分为 2.3±0.7。我们使用单导管获得了 73.3%的技术成功率,整体临床成功率(包括单导管和乒乓)为 86.7%。1 例(6.7%)患者发生心脏压塞,无研究人群因对比剂诱导的急性肾损伤(CI-AKI)需要透析。
与其他 CTO PCI 相比,经逆行途径使用单导管进行 CTO PCI 是一项具有挑战性的技术。我们的研究表明,结果可接受,与其他逆行和前向 CTO PCI 登记处相当。